Therefore, THR-β selectivity plays a crucial role in drug development, where MGL-3196, a phase III compound, has the potential to become a key player in treating hyperlipidaemia and liver-related diseases, such as NASH (17). This evidence concerns the gene THRB and hyperlipidemia.